COVID-19 vaccine trials and sex-disaggregated data

Musaddique Hussain, Mehwish Fatima, Shahid Muhammad Iqbal, Muhammad Asif, Malik Saadullah, Kashif-Ur-Rehman, Imran Mukhtar, Imran Ahmad Khan, Sajid Parveen, Tehreek Fayyaz, Najia Shabbir, Aisha Kanwal, Saira Shaukat, Mobeen Fatima, Nadia Ikram, Abdul Majeed, Farzana Parveen, Muhammad Tariq, Muhammad Qasim Barkat, Ling-Hui Zeng, and Ximei Wu

*Department of Pharmacology, Faculty of Pharmacy, The Islamia University of Bahawalpur, Bahawalpur, Pakistan; ‡Department of Pharmaceutical Chemistry, Government College University, Faisalabad, Pakistan; §Faculty of Pharmacy, Bahauddin Zakariya University, Multan Pakistan; ¶Lahore Pharmacy College (LMDC), Lahore, Pakistan; ‖Department of Pharmacology, School of Medicine, Zhejiang University, Hangzhou City, China; #Department of Pharmacology, Zhejiang University City College, Hangzhou, China

ARTICLE HISTORY Received 3 September 2021; Accepted 3 December 2021

1. COVID-19 vaccine trials and sex-disaggregated data

In the pandemic era, global immunization programs against COVID-19 are being implemented. Serious adverse events after COVID-19 vaccination are rare but may occur that include anaphylaxis, thrombosis with thrombocytopenia syndrome (TTS), myocarditis, and pericarditis [1]. Non-serious adverse reactions following COVID-19 vaccination include headache, dizziness, injection site pain, lethargy, nausea, fever, musculoskeletal pain, chest discomfort, feeling of body temperature change, and numbness.

It is the right time to remind the regulatory authorities and researchers about the significance of biological sex as a variable in trial data analysis and reporting [2] because vaccine efficacy and safety may be sex-dependent as well as COVID-19 does not strike the sexes equally [3]. Data collected from ClinicalTrials.gov, for the period 1 January 2020 to 26 January 2021, regarding inclusion of sex and/or gender in COVID-19 studies, revealed 4,420 registered SARS-CoV-2/COVID-19 studies. Among them, 21.2% (935 studies) address sex/gender solely in the context of recruitment, 5.4% (237 studies) plan sex-matched or representative samples or emphasized sex/gender reporting, and only 4% (178 studies) explicitly report a plan to include sex/gender as an analytical variable. Until 15 December 2020, just 8 (17.8%) out of the 45 COVID-19-related clinical trials were published in scientific journals that reported sex-disaggregated results or subgroup analyses [4]. Consistently, a smaller study including 30 COVID-19 trials published in January 2021 revealed that none of the studies investigated effect modification by sex [5]. Another observational study published in April 2021 revealed that only 14 out of 121 analyzed whether sex affected the results [6].

Additionally, growing evidences suggest that sex is certainly ‘just’ one factor of multiple factors affecting vaccine efficacy, while other factors include age, immune history, obesity (body mass index (BMI)), and pregnancy [7]. When weighting the different factors against each other, immune history, in particular, pre-vaccination status, is certainly the (trivially) most important factor of vaccine response and further protection against infectious diseases. Furthermore, disparities, e.g., between the sexes, but also between other host factors, are context dependent. For example, sex was a significant determinant of seroconversion to H1N1 influenza vaccine. However, the male-bias as H1N1 vaccine response was not observed in seroconversion against the H3N2 virus. Immunosenescence, which refers to the age-associated decline in immune responses, has been shown to impact immunity, and has been recognized as a significant factor, with different dosage regimes between older and younger adults (and the special treatment in the case of young children due to their unique immune response). Another factor is BMI. Under specific conditions, BMI seems to be a larger factor for seroconversion outcome than sex. In addition, antibody responses decline with greater BMI in females but not in males [8]. Pregnancy, associated with physiological and immunological changes, contributes to immunological shifts in pregnant compared to nonpregnant females. Pregnant females are at higher risk of virus infection compared to nonpregnant females. In order to develop safe, immunogenic, and highly efficacious vaccines, pregnancy-associated changes and their impact on vaccine-induced immunity should be considered in experimental studies [7].

Why it is necessary to know about biological sex related, as well as sex-disaggregated survey? Biological sex has an impact on vaccine-induced humoral immunity [9] and clinically important health outcomes, such as sex-specific differences in pharmacology, immune response, and vaccine outcomes including efficacy and side effects [10].

With COVID-19, approximately 15 men die for every 10 women, and for every 18 COVID-19 intensive care unit (ICU) admissions among men, there are 10 COVID-19 ICU admissions for women. According to data from the Centers for
Table 1. The most promising vaccines, the clinical phases, platforms, and their developers [19].

| Vaccine               | Development Phase | Platform                                | Developer                                                                 |
|-----------------------|-------------------|-----------------------------------------|---------------------------------------------------------------------------|
| AZD1222               | Phase IV          | Virus vector (ChAdOx1)                  | University of Oxford/AstraZeneca, UK                                       |
| Inactivated SARS-CoV-2 vaccine (Vero cell) | Phase IV | Inactivated virus                        | Sinopharm + China National Biotech Group Co + Wuhan Institute of Biological Products |
| CoronaVac             | Phase IV          | Inactivated virus                        | Sinovac Research and Development Co., Ltd.                                |
| BBIBP-CoV             | Phase IV          | Inactivated virus                        | Beijing Institute of Biological Products/Sinopharm, China                 |
| Ad5-nCov             | Phase IV          | Virus vector (Ad5)                      | CanSino Biological, Inc./Beijing Institute of Biotechnology, China        |
| Ad26.COV2.S           | Phase IV          | Virus-vectorized (Ad26)                 | Janssen Pharmaceuticals, USA                                              |
| mRNA-1273            | Phase IV          | LNP-mRNA                                | Moderna/NIAD, USA                                                         |
| BNT162b2             | Phase IV          | LNP-mRNA                                | BioNTech SE and Pfizer, Inc., USA                                         |
| Sputnik V            | Phase III         | Virus vector (Ad26 and Ad5)             | Gamaleya Research Institute, Russia                                       |
| NVX-CoV2373          | Phase III         | Protein subunit (CHO)                   | Novavax, USA                                                              |
| Recombinant SARS-CoV-2 vaccine | Phase III | Protein subunit (CHO)                   | Anhui Zhifei Longcom Biopharmaceutical + Institute of Microbiology, Chinese Academy of Sciences |
| WIBP-CoV             | Phase III         | Inactivated virus                        | Wuhan Institute of Biological Products/Sinopharm, China                  |
| CvnCoV Vaccine       | Phase III         | RNA-based vaccine                        | CureVac AG                                                                |
| SARS-CoV-2 vaccine (Vero cells) | Phase III | Inactivated virus                        | Institute of Medical Biology + Chinese Academy of Medical Sciences        |
| BBV152               | Phase III         | Inactivated virus                        | Bharat Biotech BBV152 vaccine                                            |
| Coronavirus           | Phase III         | Virus-like particle                      | Medicago Vaccine                                                          |
| like particle         |                   |                                         |                                                                          |
| QazCovid             | Phase III         | Inactivated virus                        | Research Institute for Biological Safety Problems, Rep of Kazakhstan     |
| INO-4800             | Phase III         | DNA-based vaccine                        | Inovio Pharmaceuticals + International Vaccine Institute + Advaccine (Suzhou)Biopharmaceutical Co., Ltd. |
| nCoV vaccine         | Phase III         | DNA-based vaccine                        | Zyduz Cadila                                                             |
| sinophar              | Phase III         | Inactivated virus                        | Bharat Biotech International Limited                                     |
| VAT00002             | Phase III         | Protein subunit                          | Sanofi Pasteur + GSK                                                     |
| Inactivated SARS-CoV-2 vaccine (Vero cell) | Phase III | Inactivated virus                        | Shenzhen Kangtai Biological Products Co., Ltd.                            |
| SCB-2019 + AS03      | Phase III         | Protein subunit                          | Clover Biopharmaceuticals Inc./GSK/Dynavax                               |
| COVAX-19             | Phase III         | Protein subunit                          | Vaxine Pty Ltd./Cinnagen Co.                                              |
| MVC-COV1901          | Phase III         | Protein subunit                          | Medigen Vaccine Biologics + Dynavax + National Institute of Allergy and Infectious Diseases (NIAD) |
| FINLAY-FR-2 anti-SARS-CoV-2 Vaccine | Phase III | Protein subunit                          | Instituto Finlay de Vacunas                                               |
| EpiVacCorona         | Phase III         | Protein subunit                          | Federal Budgetary Research Institution State Center of Virology and Biotechnology 'Vector' |
| Recombinant SARS-CoV-2 vaccine (S9 Cell) | Phase III | Protein subunit                          | West China Hospital + Sichuan University                                  |
| DelNS1-2019-nCoV-RBD-OPT1 | Phase III | Viral vector (Replicating)               | University of Hong Kong, Xiamen University and Beijing Wantai Biological Pharmacy |
| ARCoV                | Phase III         | RNA-based vaccine                        | Academy of Military Science (AMS), Walvax Biotechnology and Suzhou Abogen Biosciences |
| COVI-VAC             | Phase III         | Live attenuated virus                    | Codagenix/Serum Institute of India                                        |
| CIG-66               | Phase III         | Protein subunit                          | Center for Genetic Engineering and Biotechnology (CIGB)                   |
| VLA2001              | Phase III         | Inactivated Virus                        | Valneva, National Institute for Health Research, United Kingdom           |
| BECOV2               | Phase III         | Protein subunit                          | Biological E. Limited                                                    |
| Nanocovax            | Phase III         | Protein subunit                          | Nanogen Pharmaceutical Biotechnology                                     |
| ERUCOV-VAC, inactivated virus | Phase III | Inactivated Virus                        | Ercyes University, Turkey                                                |

Disease Control and Prevention, there is a gender gap in vaccination coverage, with women several percentage (almost 6%) points higher than men [11]. ChAdOx1 nCoV-19 (AstraZeneca’s vaccines) and Ad26.COV2.S or JNJ-78436735 (Johnson & Johnson’s vaccines) cause rare clotting disorders in women [12–15], whereas BNT162b2 (Pfizer-BioNTech’s vaccines) and mRNA-1273 (Moderna’s vaccines) are more likely to cause anaphylaxis in females, and mRNA-1273 caused large local rashes in more females and than males, but myocarditis was more common in males [16–18]. But investigators have not yet reported or discussed how data could be impacted by biological sex. In the future, a report on how sex-disaggregated data and sexual factors affect trial results will help regulatory and public decision-making as well as the development of mass vaccination programs. Clinical trials of Phase III and IV are depicted in Table 1.  

Multiple clinical trials of the vaccine have shown that there is a difference between men and women that exist across the entire life span: women have a strong immune response to the vaccine that can assist vaccine efficacy, but they often experience more recurrent and more severe side effects [20–23]. Additionally, vaccine studies reveal that cisgender females have a greater ability to produce higher antibody response, and relatively, greater efficacy as well as side effects, recommending the requirement for sex-differentiated dosing schedule [10,24].

Studies on influenza vaccines have shown that women’s immunological response to half-dose vaccines is the same as men’s to full-dose vaccines [25]. In SARS-CoV-2 infections, sex-based differences in adaptive and innate immunity are likely contributors to increased risk of intensive care unit admission and overall death in men as well as increased reporting of long COVID-19 symptoms in women [26]. Hence, the impact of
sex factors on immune responses may be present in COVID-19 vaccine-induced immunity and adverse outcomes.

We now have the opportunity to course-correct the integration of biological sex as a core variable in research reporting, design, and analysis because sex factors (sex-disaggregated analysis and reporting) are being ignored globally during the era of COVID-19 vaccine innovative research and regulation [27] as well as in COVID-19 trial data reporting (8 from lancet). A review of approximately 2,500 COVID-19-related studies revealed that less than 5% of researcher/investigators had intended for sex-disaggregated data analysis in their research [28]. Recently, a systematic review and meta-analysis revealed that the correlation between sex and COVID-19 vaccine efficacy and safety should be considered in enhancing vaccine decision-making programs [29]. Vaccine trial reports those included sex-disaggregated primary outcomes data should be applauded [30,31]. Hence, the correlation between sexual orientation (physiological characteristics of the genitals and sex hormones) and the effectiveness of the COVID-19 vaccine must be considered in enhancing vaccine decision-making plans, and mentioning sex-disaggregated adverse reactions and secondary consequences would be beneficial in future reports.

However, sex-disaggregated-based analysis and reporting benchmark would be collectively set not only for future candidate of COVID-19 vaccines but also for all pharmaceuticals, biologicals, and other therapeutic interventions present in the research pipelines.

Funding

This paper was not funded.

Declaration of interests

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Reviewer disclosures

Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

References

1. Centers for Disease Control and Prevention. Selected adverse events reported after COVID-19 vaccination. 2021. [Cited 2021 Oct 24].
2. Bischof E, Wolfe J, Klein SL. Clinical trials for COVID-19 should include sex as a variable. J Clin Invest. 2020;130:3350–3352.
3. Meredith W. Why coronavirus hits men harder: sex hormones offer clues. Science. 2020 doi:10.1126/science.abc1288.
4. Brady E, Nielsen MW, Andersen JP, et al. Lack of consideration of sex and gender in COVID-19 clinical studies. Nat Commun. 2021;12 (1):1–6.
5. Schiffer VM, Jansen EB, van Bussel BC, et al. The “sex gap” in COVID-19 trials: a scoping review. EClinicalMedicine. 2020;29:30:100652.
6. Palmer-Ross A, Osveiko PV, Heidari S. Inadequate reporting of COVID-19 clinical studies: a renewed rationale for the Sex and Gender Equity in Research (SAGER) guidelines. BMJ Glob Health. 2021;6(4):e004997.
7. Dhakal S, Klein SL. Host factors impact vaccine efficacy: implications for seasonal and universal influenza vaccine programs. J Virol. 2019;93(21):e00797–19.
8. Kuo H, Shapiro JR, Dhakal S, et al. Sex-specific effects of age and body mass index on antibody responses to seasonal influenza vaccines in healthcare workers. Vaccine. 2021. DOI:10.1016/j.vaccine.2021.02.047
9. Fischinger S, Boudreau CM, Butler AL, et al. Sex differences in vaccine-induced humoral immunity. Semin Immunopathol. 2019;41(2):239–249. Springer Berlin Heidelberg.
10. Flanagan KL, Fink AL, Plebanski M, et al. Sex and gender differences in the outcomes of vaccination over the life course. Ann Rev Cell Develop Biol. 2017;33:577–599.
11. Puzio A. Why is there such a gender gap in COVID-19 vaccination rates? ABC news. 2021 Jun 22. [Cited 2021 Aug 24]. Available from: https://fivethirtyeight.com/features/why-is-there-such-a-gender-gap-in-covid-19-vaccination-rates/
12. Kupferschmidt K, Vogel G. What’s the future of vaccines linked to rare clotting disorders? Science breaks down the latest. Science. May 3 2021 [cited 2021 Aug 24]. Available from: https://www.sciencemag.org/news/2021/05/what-s-future-vaccines-linked-rare-clotting-disorders-science-breaks-down-lates
13. Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397:99–111.
14. Bendix A. Rare blood clots following both the AstraZeneca and J&J vaccines might be no coincidence — they share the same technology. Insider. 2021 Apr 15. [cited 2021 Oct 23]. Available from: https://www.businessinsider.com/astrazeneca-johnson-and-johnson-rare-blood-clots-similar-2021-4
15. Katella K. The Johnson & Johnson vaccine and blood clots: what you need to know. Yale Medicine. 14 Aug 2021 [cited 2021 Oct 23]. Available from: https://www.yalemedicine.org/news/coronavirus-vaccine-blood-clots
16. Mevorach D, Anis E, Cedar N, et al. Myocarditis after BNT162b2 mRNA vaccine against COVID-19 in Israel. N Engl J Med. 2021;385 (23):2140–2149.
17. Vogel G, Cousin-Frankel J. Israel reports link between rare cases of heart inflammation and COVID-19 vaccination in young men. Science. 2021 Jun 1. [cited 2021 Aug 23]. Available from: https://www.sciencemag.org/news/2021/06/Israel-reports-link-between-rare-cases-heart-inflammation-and-covid-19-vaccination
18. Katella K. Comparing the COVID-19 vaccines: how are they different? Yale Medicine. 2021 Oct 22. [cited 2021 Oct 23]. Available from: https://www.yalemedicine.org/news/covid-19-vaccine-comparison
19. World Health Organization. COVID-19 vaccine tracker and landscape. [Cited 23 Oct 2021]. Available from: https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines
20. Fink AL, Klein SL. Sex and gender impact immune responses to vaccines among the elderly. Physiology. 2015;30(6):408–416.
21. Fink AL, Klein SL. The evolution of greater humoral immunity in females than males: implications for vaccine efficacy. Curr Opin Physiol. 2018;6:16–20.
22. Fischinger S, Boudreau CM, Butler AL, et al. Sex differences in vaccine-induced humoral immunity. Semin Immunopathol. 2019;41(2):239–249.
23. Flanagan KL, Fink AL, Plebanski M, et al. Sex and gender differences in the outcomes of vaccination over the life course. Ann Rev Cell Dev Biol. 2017;33:577–599.
24. Zimmermann P, Curtis N. Factors that influence the immune response to vaccination. Clin Microbiol Rev. 2019;32:e0084–18.
25. Engler RJM. Half- vs full-dose trivalent inactivated influenza vaccine (2004–2005): age, dose, and sex effects on immune responses. Arch Intern Med. 2008;168:2405.

26. Sudre CH, Murray B, Varsavsky T, et al. Attributes and predictors of long-COVID: analysis of COVID cases and their symptoms collected by the covid symptoms study app. medRxiv. 2020. published online Oct 21. (preprint). DOI:10.1101/2020.09.13.20193680.

27. Ravindran TS, Teerawattananon Y, Tannenbaum C, et al. Making pharmaceutical research and regulation work for women. BMJ. 2020;371:m3808.

28. Brady E, Nielsen MW, Andersen JP, et al. Lack of consideration of sex and gender in clinical trials for COVID-19. medRxiv. 2020; published online Sept 14. (preprint). DOI:10.1101/2020.09.13.20193680.

29. Bignucolo A, Scarabel L, Mezzalira S, et al. Sex disparities in efficacy in COVID-19 vaccines: a systematic review and meta-analysis. Vaccines (Basel). 2021;9(8):825.

30. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383:2603–2615.

31. Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384:403–416.